Neurocrine Biosciences Newsroom

Neurocrine Biosciences, Inc. Selects PANTHERxRare Specialty Pharmacy for Distribution of Crenessity (Crinecerfont)

PR Newswire03:54

Neurocrine Is Maintained at Overweight by Barclays

Dow JonesDec 23 20:49 · Ratings

Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $160

Futu NewsDec 23 20:31 · Ratings

Wedbush Raises Price Target on Neurocrine Biosciences to $154 From $148, Keeps Outperform Rating

MT NewswiresDec 23 19:39 · Ratings

Barclays Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165

Futu NewsDec 23 18:34 · Ratings

Express News | Neurocrine Biosciences Inc : Jefferies Raises Target Price to $168 From $158

BreakingsDec 23 14:25

Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?

BenzingaDec 22 22:51

Needham Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating

Futu NewsDec 21 03:31 · Ratings

TD Cowen Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165

Futu NewsDec 21 03:31 · Ratings

BofA Securities Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $182

Futu NewsDec 21 03:31 · Ratings

TD Cowen Reaffirms Their Buy Rating on Neurocrine (NBIX)

TipRanksDec 21 02:43 · Ratings

Neurocrine Biosciences Starts Commercial Sales of New Congenital Adrenal Hyperplasia Treatment

MT NewswiresDec 21 00:53

Needham Reiterates Hold on Neurocrine Biosciencesto Hold

BenzingaDec 20 23:52

Express News | Neurocrine Biosciences Announces Commercial Availability of Crenessity™ (Crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

BreakingsDec 20 21:00

J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $185

Futu NewsDec 18 20:34 · Ratings

A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $148 to $190

Futu NewsDec 17 21:00 · Ratings

Express News | Neurocrine Biosciences Inc : JP Morgan Raises Target Price to $185 From $184

BreakingsDec 17 13:20

Summit Therapeutics Shares Are Trading Higher. The Stock May Be Moving in Sympathy With Neurocrine Biosciences Which Received FDA Approval for CRESNESSITY.

BenzingaDec 17 04:23

Neurocrine Biosciences Rises on FDA Nod for CAH Drug

InvestingDec 17 00:26

Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential

Analyst UpgradesDec 16 22:10